UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 68 filers reported holding UROGEN PHARMA LTD in Q1 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,146 | +31.3% | 81,831 | -3.0% | 0.28% | +13.1% |
| Q2 2023 | $873 | +12.1% | 84,331 | 0.0% | 0.25% | +2.4% |
| Q1 2023 | $779 | +4.1% | 84,331 | 0.0% | 0.25% | 0.0% |
| Q4 2022 | $748 | -99.9% | 84,331 | 0.0% | 0.25% | -5.0% |
| Q3 2022 | $702,000 | +1.6% | 84,331 | 0.0% | 0.26% | -5.5% |
| Q2 2022 | $691,000 | -6.0% | 84,331 | 0.0% | 0.27% | -5.5% |
| Q1 2022 | $735,000 | -10.4% | 84,331 | -2.2% | 0.29% | -19.7% |
| Q4 2021 | $820,000 | -43.5% | 86,254 | 0.0% | 0.36% | -58.6% |
| Q3 2021 | $1,451,000 | +10.2% | 86,254 | 0.0% | 0.87% | +10.1% |
| Q2 2021 | $1,317,000 | -21.6% | 86,254 | 0.0% | 0.79% | -33.5% |
| Q1 2021 | $1,680,000 | +8.1% | 86,254 | 0.0% | 1.19% | -8.3% |
| Q4 2020 | $1,554,000 | – | 86,254 | – | 1.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |